AD 05Alternative Names: Ab-AD05; AD-05; Affitope-AD05
Latest Information Update: 13 Sep 2016
At a glance
- Originator AFFiRiS
- Class Alzheimer vaccines
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 08 Sep 2016 Preclinical trials in Alzheimer's disease in Austria (Parenteral) before September 2016 (AFFiRis pipeline, September 2016)